Browsing Tag
Penumbra
4 posts
Boston Scientific (BSX) Q2 2026 beats estimates as MiRus TAVR investment reshapes strategy
Boston Scientific lifted FY 2026 guidance and disclosed a $1.5B MiRus TAVR bet, but BSX trades near 52-week lows as softer Q3 growth guidance stings.
Could THUNDERBOLT sharpen Penumbra’s stroke portfolio before the Boston Scientific deal closes?
Find out how Penumbra’s THUNDERBOLT FDA clearance could reshape stroke thrombectomy and computer assisted clot removal.
Penumbra (NYSE: PEN) says STORM-PE 90-day data strengthens case for thrombectomy in pulmonary embolism
Penumbra’s new STORM-PE data showed stronger 90-day recovery in pulmonary embolism patients. Read what it means for growth, competition, and care.
Boston Scientific to acquire Penumbra for $14.5bn in transformative vascular and neurovascular expansion move
Boston Scientific’s $14.5B acquisition of Penumbra signals an aggressive move into neurovascular and thrombectomy markets. Find out what this means for medtech.